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Background: We previously reported cilostazol reduces the incidence of restenosis in patients treated with cobalt-chromium alloy stents (CCS). 
However, there is uncertainty about the effectiveness of cilostazol in patients at high risk for restenosis.
Methods: A total of 346 patients with de novo coronary stenosis who underwent CCS implantation were assigned to receive aspirin plus 
thienopyridine plus cilostazol (triple group, n=173) or aspirin plus thienopyridine (dual group, n=173) from August 2006 to March 2009. Patients 
with two or three risk factors for restenosis (i.e., presence of diabetes, small vessels [<3 mm in diameter], and long lesions [>15 mm]) were 
classified as high risk, and the other patients were classified as low risk. The primary end point was in-stent late loss at 6 months. The secondary end 
points were in-segment late loss and binary restenosis rate at 6 months, target lesion revascularization, target vessel revascularization (TVR), and 
major adverse cardiac events, including death, myocardial infarction, and TVR at 1 year.
Results: Among high-risk (n=165) and low-risk (n=181) patients, baseline clinical and angiographic characteristics were similar between the triple 
and dual groups. Follow-up angiography was performed in 86% of patients. Among high-risk patients, the in-stent (0.56±0.47 vs. 1.00±0.64 mm, 
p<0.001) and in-segment (0.23±0.46 vs. 0.61±0.62 mm, p<0.001) late loss were significantly smaller in the triple group than in the dual group. 
Among low-risk patients, the in-stent (0.47±0.57 vs. 0.86±0.55 mm, p<0.001) and in-segment (0.27±0.53 vs. 0.52±0.57 mm, p=0.006) late loss 
were also significantly smaller in the triple group. The triple group has more pronounced effect on in-segment binary restenosis in high-risk (8.2% vs. 
25.6%, p=0.008, number needed to treat (NNT) =5.7) than low-risk (3.5% vs. 13.5%, p=0.039, NNT=10) patients. One-year clinical follow-up data 
will be presented at the meeting.
Conclusions: Although cilostazol showed significant reduction of late loss and restenosis rate after CCS implantation regardless of the risk for 
restenosis, reduction of restenosis was more prominent in high-risk than low-risk patients.
